The persistence of vaccine-induced HBsAg-specific antibodies and immune memory in adults after complete primary vaccination with the GlaxoSmithKline (GSK) hexavalent Infanrix vaccine at infancy (HEP-IMMUNE)

Study identification

• EU PAS number:
  EUPAS1000001160
• Study ID:
  1000001160
• Official title and acronym:
  The persistence of vaccine-induced HBsAg-specific antibodies and immune memory in adults after complete primary vaccination with the GlaxoSmithKline (GSK) hexavalent Infanrix vaccine at infancy (HEP-IMMUNE)
• DARWIN EU® study:
  No
• Study countries:
  Belgium
• Study description:
  In this study, long-term persistence of cellular and humoral immunity against hepatitis B is investigated in students (around 20 YOA) vaccinated with Infanrix-Hexa during infancy. In study participants with HBsAg-specific antibody level titers < 10 mIU/mL, the immune response to a booster vaccination with Engerix-B is explored.
• Study status:
  Ongoing

Research institutions and networks

Institutions

University of Antwerp

Study timelines

Date when funding contract was signed

Actual:23/06/2026

Study start date

Actual:29/09/2026

Date of final study report

Planned:31/12/2027

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

This study was supported as an Investigator-Sponsored Study (ISS) within the Supported Studies Programme of GSK (internal trial identifier IIS 24004/308887).

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable